Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent

This article was originally published in The Pink Sheet Daily

Executive Summary

Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.

You may also be interested in...



Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try

CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.

Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try

CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.

Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase

Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel